Drugs with Coverage Limitations and New Drug Review
Please Note:
- Date Review Completed and Conclusion columns are blank for those products currently undergoing review. Details will be updated as efficiently as possible following initial review.
- Conclusions are based upon decisions made at the time reviews are completed; historical information is not updated. Product management is subject to change based on new clinical evidence, provider/public feedback, advisory committee recommendations, financial considerations, etc.
- This contains approximately one year of New Drug details.
- Advisory Meeting Month is the month this recommendation will be presented at the quarterly Drug Prior Authorization Committee (DPAC) and Drug Utilization Review (DUR) Board meetings. For meeting dates, please see the MO HealthNet Calendar of Events. Certain agents may also be discussed at the quarterly Rare Disease Advisory Council meeting immediately prior to their presentation at their designated DPAC/DUR meeting.
For more information on this process please view the New Drug Review Process or contact the MO HealthNet Pharmacy Program at MHD.PharmacyAdmin@dss.mo.gov or call 573-751-6963.
| Trade Name | Generic Name | Date Review Began | Date Review Completed | Conclusion | Advisory Committee Month |
|---|---|---|---|---|---|
| NUCALA 40 MG/0.4 ML SYRINGE | MEPOLIZUMAB | 06/19/2022 | 08/11/2022 | PDL Product | September 2022 / October 2022 |
| TYVASO DPI 64 MCG CARTRIDGE | TREPROSTINIL | 06/12/2022 | 08/02/2022 | PDL Edit | September 2022 / October 2022 |
| BYOOVIZ 0.5 MG/0.05 ML VIAL | RANIBIZUMAB-NUNA | 06/12/2022 | 08/02/2022 | PDL Edit | September 2022 / October 2022 |
| TYVASO DPI 48 MCG CARTRIDGE | TREPROSTINIL | 06/12/2022 | 08/02/2022 | PDL Edit | September 2022 / October 2022 |
| TYVASO DPI 32-48 MCG MAINT KIT | TREPROSTINIL | 06/12/2022 | 08/02/2022 | PDL Edit | September 2022 / October 2022 |
| TYVASO DPI 32 MCG CARTRIDGE | TREPROSTINIL | 06/12/2022 | 08/02/2022 | PDL Edit | September 2022 / October 2022 |
| TYVASO DPI 16-32-48 MCG TITRAT | TREPROSTINIL | 06/12/2022 | 08/02/2022 | PDL Edit | September 2022 / October 2022 |
| TYVASO DPI 16-32 MCG TITR KIT | TREPROSTINIL | 06/12/2022 | 08/02/2022 | PDL Edit | September 2022 / October 2022 |
| TYVASO DPI 16 MCG CARTRIDGE | TREPROSTINIL | 06/12/2022 | 08/11/2022 | PDL Edit | September 2022 / October 2022 |
| CAMZYOS 2.5 MG CAPSULE | MAVACAMTEN | 06/05/2022 | 08/11/2022 | Clinical Edit | September 2022 / October 2022 |
| CAMZYOS 15 MG CAPSULE | MAVACAMTEN | 06/05/2022 | 08/11/2022 | Clinical Edit | September 2022 / October 2022 |
| CAMZYOS 10 MG CAPSULE | MAVACAMTEN | 06/05/2022 | 08/02/2022 | Open Access | September 2022 / October 2022 |
| BEOVU 6 MG/0.05 ML SYRINGE | BROLUCIZUMAB-DBLL | 06/05/2022 | 08/02/2022 | PDL Edit | September 2022 / October 2022 |
| ADLARITY 5 MG/DAY PATCH | DONEPEZIL HCL | 06/05/2022 | 08/02/2022 | PDL Edit | September 2022 / October 2022 |
| CAMZYOS 5 MG CAPSULE | MAVACAMTEN | 06/05/2022 | 08/11/2022 | Clinical Edit | September 2022 / October 2022 |